Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNC 105

Drug Profile

BNC 105

Alternative Names: BNC 105P; BNC-105

Latest Information Update: 28 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Iliad Chemicals
  • Developer Bionomics
  • Class Anisoles; Antineoplastics; Benzofurans; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Mesothelioma; Renal cell carcinoma
  • Phase I/II Ovarian cancer
  • No development reported Chronic lymphocytic leukaemia; Colorectal cancer

Most Recent Events

  • 28 Jul 2019 No recent reports of development identified for preclinical development in Colorectal-cancer in Australia (IV, Infusion)
  • 24 Jun 2018 Biomarkers information updated
  • 28 May 2018 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top